Argent BioPharma Director’s Interests Update

Argent Biopharma (AU:RGT) has released an update.

Argent BioPharma Limited has notified the ASX of a change in Director Roby Reuven Zomer’s interests, due to the expiry of 2,500 performance rights and 2,400 Class C performance rights, both with zero cash value. Following the change, Zomer indirectly maintains 1 fully paid ordinary share through Chitta Lu Limited and 33,820 fully paid ordinary shares through HSBC Custody Nominees (Australia) Limited.

For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.